Fundraising Fox
Savran Technologies
Newton, US · Founded 2018 · 10 employees on LinkedIn · 2 known investors
Find your way into Savran Technologies
Each arrow is one introduction. Sign up to fill in the first one.
268 people can intro you to Nadia
Ask Andrew Elder to introduce you to Nadia Altomare
You →Andrew · together at ABCODIA LIMITED →Nadia
Sign up to find every way you can get introduced to Savran Technologies
- Your email: who you already know at Savran Technologies, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Savran Technologies team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
SavranTech is a diagnostics company developing non-invasive, cell-based diagnostic tests for women's health, starting with preeclampsia, and spanning maternal health, prenatal care, and oncology. Its patented platform serves clinicians and healthcare in the women's health diagnostics category.
Founders & leadership
Savran Technologies was founded in 2018 by Cagri Savran.
CS
Cagri SavranFounder
NA
Nadia AltomareBoard Of DirectorsNadia Altomare is Director at Savran Technologies and brings over 20 years of experience in biotech and diagnostics leadership, including prior roles as Chief Commercial Officer at Sera Prognostics, CEO at Abcodia Ltd, and Vice President & General Manager at ThermoFisher Scientific where she led the ViaCord division startup and scaling.
Board
SD
JB
Jeffrey BehrensBoard director
MC
Investors · 2
Walnut Venture Associateslisted by Walnut Venture AssociatesWellesley
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 6 rounds · 2018–2024
▶$424.7KraisedSep 2024 · 30 investors · BiotechnologyRule 506(b)
▶$424.7KraisedSep 2024 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cagri SavranExecutive Officer, Director
- Nadia AltomareDirector
- Sal DaherDirector
- Jeffrey BehrensDirector
- Yavuz KaynarDirector
- Offering amount
- $2M
- Amount sold
- $424.7K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$304.4KraisedMar 2023 · 18 investors · BiotechnologyRule 506(b)
▶$304.4KraisedMar 2023 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cagri SavranExecutive Officer, Director
- Sal DaherDirector
- Jeffrey BehrensDirector
- Nadia AltomareDirector
- Yavuz KaynarDirector
- Amount sold
- $304.4K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedDec 2021 · 52 investors · BiotechnologyRule 506(b)
▶$4.2MraisedDec 2021 · 52 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cagri SavranExecutive Officer, Director
- Yavuz KaynarDirector
- Nadia AltomareDirector
- Sal DaherDirector
- Jeffrey BehrensDirector
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$208KraisedMay 2020 · 11 investors · BiotechnologyRule 506(b)
▶$208KraisedMay 2020 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff BehrensDirector
- Simon W. TurnerExecutive Officer
- Nadia AltomareDirector
- Cagri SavranExecutive Officer, Director
- Saleh DaherDirector
- Offering amount
- $300K
- Amount sold
- $208K
- Minimum investment
- $10K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25KraisedFeb 2019 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedFeb 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cagri SavranExecutive Officer, Director
- Mark CarthyDirector
- Offering amount
- $500K
- Amount sold
- $25K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1.1MraisedOct 2018 · 29 investors · BiotechnologyRule 506(b)
▶$1.1MraisedOct 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick RivelliExecutive Officer, Director
- Mark CarthyDirector
- Cagri SavranDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Savran Technologies do?
- SavranTech is a diagnostics company developing non-invasive, cell-based diagnostic tests for women's health, starting with preeclampsia, and spanning maternal health, prenatal care, and oncology. Its patented platform serves clinicians and healthcare in the women's health diagnostics category.
- Who founded Savran Technologies?
- Savran Technologies was founded by Cagri Savran in 2018.
- Who are Savran Technologies's investors?
- Savran Technologies's investors include TBD Angels, Walnut Venture Associates.
- How much funding has Savran Technologies raised?
- Savran Technologies has disclosed $6.2M raised across 6 rounds.
- Where is Savran Technologies headquartered?
- Savran Technologies is headquartered in Newton, US.